Elanco’s $135 Million Divestiture of Dechra Pharmaceuticals Product

Covington represented Elanco Animal Health in the transaction.

Elanco Animal Health entered into an agreement with Dechra Pharmaceuticals to divest Osurnia® for $135 million in an all-cash deal.

Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in animals and pets in more than 90 countries.

Dechra Pharmaceuticals PLC is an international pharmaceutical business focused on the veterinary market, with its key area of specialisation being the development and marketing of companion animal products. Osurnia® is a treatment for otitis externa in dogs.

The Covington team included Michael Riella (Picture), Catherine Dargan, Lauren Visek, and Andrew Barna.

Involved fees earner: Andrew Barna – Covington & Burling; Catherine Dargan – Covington & Burling; Michael Riella – Covington & Burling; Lauren Visek – Covington & Burling;

Law Firms: Covington & Burling;

Clients: Elanco US, Inc.;

Author: Ambrogio Visconti